Author

B.X. Wang

Observed names: BX Wang, Ben X. Wang

Institution: Princess Margaret Cancer Centre

Observed institutions: University Health Network, University of Toronto, Princess Margaret Cancer Centre

OpenAlex ID: A5014511268

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)

2023 · A. Spreafico, A.A. Heirali, et al. · Annals of Oncology · 95

Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib – A phase II trial (PEMRAD)

2025 · Grainne M. O’Kane, Aruz Mesci, et al. · JHEP Reports · 6

Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient

2023 · SC Lien, D Ly, et al. · immuneACCESS · 4

OA12.04 Radiation Reprograms CDKN2A/p16 Wild Type Epithelioid Mesothelioma Towards an Immune Responsive Tumor Microenvironment

2025 · M. De Perrot, A. Zia, et al. · Journal of Thoracic Oncology · 1

1298P PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy

2021 · S.C. Lau, M.J. Elliott, et al. · Annals of Oncology · 1

Cross-Cancer Analysis Reveals Distinct Pattern of Immune Modulation during Curative Radiotherapy

2024 · B. Id Said, G. Boukhaled, et al. · International Journal of Radiation Oncology*Biology*Physics

1005P Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)

2024 · P. Spiliopoulou, M. Wong, et al. · Annals of Oncology

Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with pembrolizumab in the INSPIRE study

2018 · M. Oliva Bernal, S. Lien, et al. · Annals of Oncology

Works count: 8

Citation count: 107

H-index: 3

I10-index: 1